S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

リアルタイムの更新: Luye Pharma Group Ltd [2186.HK]

取引所: HKSE 産業: Pharmaceuticals, Biotechnology & Life Sciences
最終更新日時26 4月 2024 @ 17:08

0.74% HKD 2.72

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 17:08):

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia...

Stats
本日の出来高 25.13M
平均出来高 9.60M
時価総額 10.23B
EPS HKD0 ( 2024-03-28 )
Last Dividend HKD0.0600 ( 2020-06-29 )
Next Dividend HKD0 ( N/A )
P/E 18.13
ATR14 HKD0.00900 (0.33%)

ボリューム 相関

長: 0.11 (neutral)
短: 0.28 (neutral)
Signal:(47.09) Neutral

Luye Pharma Group Ltd 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Luye Pharma Group Ltd 相関 - 通貨/商品

The country flag -0.38
( neutral )
The country flag -0.39
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.46
( neutral )

Luye Pharma Group Ltd 財務諸表

Annual 2023
収益: HKD6.14B
総利益: HKD4.20B (68.44 %)
EPS: HKD0.140
FY 2023
収益: HKD6.14B
総利益: HKD4.20B (68.44 %)
EPS: HKD0.140
FY 2022
収益: HKD5.98B
総利益: HKD4.14B (69.22 %)
EPS: HKD0.170
FY 2021
収益: HKD5.20B
総利益: HKD3.40B (65.32 %)
EPS: HKD-0.0422

Financial Reports:

No articles found.

Luye Pharma Group Ltd Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)

Luye Pharma Group Ltd Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.62 - good (86.18%) | Divividend Growth Potential Score: 4.10 - Potential for dividend initiation, but uncertain (18.00%)
Information
First Dividend HKD0.0370 2016-10-04
Last Dividend HKD0.0600 2020-06-29
Next Dividend HKD0 N/A
Payout Date 2020-07-24
Next Payout Date N/A
# dividends 8 --
Total Paid Out HKD0.406 --
Avg. Dividend % Per Year 0.00% --
Score 2.99 --
Div. Sustainability Score 8.62
Div.Growth Potential Score 4.10
Div. Directional Score 6.36 --
Next Divdend (Est)
(2024-08-02)
HKD0 Estimate 0.00 %
Dividend Stability
0.06 Very Bad
Dividend Score
2.99
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
2601.HK Ex Dividend Knight 2023-05-30 Annually 0 0.00%
1397.HK Ex Dividend Junior 2023-06-21 Sporadic 0 0.00%
0460.HK Ex Dividend Junior 2023-06-06 Annually 0 0.00%
6830.HK Ex Dividend Junior 2023-06-12 Annually 0 0.00%
1948.HK Ex Dividend Junior 2023-06-02 Annually 0 0.00%
0978.HK Ex Dividend Junior 2023-05-30 Annually 0 0.00%
0097.HK Ex Dividend Junior 2023-06-07 Semi-Annually 0 0.00%
3320.HK Ex Dividend Junior 2023-06-05 Annually 0 0.00%
1538.HK Ex Dividend Junior 2023-06-05 Sporadic 0 0.00%
0586.HK Ex Dividend Junior 2023-06-29 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.08671.5008.2710.00[0 - 0.5]
returnOnAssetsTTM0.02091.2009.3010.00[0 - 0.3]
returnOnEquityTTM0.04461.500-0.615-0.923[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.3150.8008.426.74[1 - 3]
quickRatioTTM0.8440.8009.747.79[0.8 - 2.5]
cashRatioTTM0.3981.5008.9010.00[0.2 - 2]
debtRatioTTM0.330-1.5004.50-6.76[0 - 0.6]
interestCoverageTTM2.561.000-0.164-0.164[3 - 30]
operatingCashFlowPerShareTTM0.1832.009.9410.00[0 - 30]
freeCashFlowPerShareTTM0.03872.009.9810.00[0 - 20]
debtEquityRatioTTM0.671-1.5007.32-10.00[0 - 2.5]
grossProfitMarginTTM0.6841.0001.9271.927[0.2 - 0.8]
operatingProfitMarginTTM0.1441.0009.119.11[0.1 - 0.6]
cashFlowToDebtRatioTTM0.08211.000-0.655-0.655[0.2 - 2]
assetTurnoverTTM0.2410.800-1.727-1.381[0.5 - 2]
Total Score8.62

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM17.771.0008.310[1 - 100]
returnOnEquityTTM0.04462.50-0.395-0.923[0.1 - 1.5]
freeCashFlowPerShareTTM0.03872.009.9910.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM0.1832.009.9410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM1.6011.5002.660[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1121.0009.690[0.1 - 0.5]
Total Score4.10

Luye Pharma Group Ltd

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。